Increase of CD4+CD25+FoxP3+Regulatory T Cells in Myeloma.

IF 0.7 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Clinical laboratory Pub Date : 2025-06-01 DOI:10.7754/Clin.Lab.2024.241208

Hee Sue Park, Suel Gi Oh, Bo Ra Son, Yong-Pyo Lee, Jihyun Kwon

{"title":"Increase of CD4+CD25+FoxP3+Regulatory T Cells in Myeloma.","authors":"Hee Sue Park, Suel Gi Oh, Bo Ra Son, Yong-Pyo Lee, Jihyun Kwon","doi":"10.7754/Clin.Lab.2024.241208","DOIUrl":null,"url":null,"abstract":"Background: In the tumor microenvironment, regulatory T cells (Treg cells), a small subset of CD4+ T cells, can interrupt antitumor immune reactions by interacting with various other immune cells. The present study aimed to determine the expression level of Treg cells in myeloma compared with that in normal control.Methods: Peripheral blood samples from 90 healthy adults and marrow aspiration samples from 13 patients newly diagnosed with myeloma were collected. Eight-color flow cytometry was performed using a Duraclone IM Treg tube kit. A gating strategy was established based on immunophenotypic characteristics of Treg cells identified as CD3+CD4+CD25+FoxP3+CD39+Helios+ cells.Results: A 2.5-fold increase in Treg cells, based on the CD4+CD25+FoxP3+ combination, was confirmed in the ini-tial myeloma diagnosis compared with the normal control. Additionally, increased Treg cells had a weak positive correlation with urine M-protein levels (r = 0.619, p < 0.05).Conclusions: Thus, an increase in Treg cells appears to potentially predict a worse complication of myeloma based on microenvironmental-related biomarkers.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 6","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.241208","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In the tumor microenvironment, regulatory T cells (Treg cells), a small subset of CD4+ T cells, can interrupt antitumor immune reactions by interacting with various other immune cells. The present study aimed to determine the expression level of Treg cells in myeloma compared with that in normal control.

Methods: Peripheral blood samples from 90 healthy adults and marrow aspiration samples from 13 patients newly diagnosed with myeloma were collected. Eight-color flow cytometry was performed using a Duraclone IM Treg tube kit. A gating strategy was established based on immunophenotypic characteristics of Treg cells identified as CD3+CD4+CD25+FoxP3+CD39+Helios+ cells.

Results: A 2.5-fold increase in Treg cells, based on the CD4+CD25+FoxP3+ combination, was confirmed in the ini-tial myeloma diagnosis compared with the normal control. Additionally, increased Treg cells had a weak positive correlation with urine M-protein levels (r = 0.619, p < 0.05).

Conclusions: Thus, an increase in Treg cells appears to potentially predict a worse complication of myeloma based on microenvironmental-related biomarkers.

查看原文本刊更多论文

骨髓瘤中CD4+CD25+FoxP3+调节性T细胞的升高。

背景：在肿瘤微环境中，调节性T细胞（Treg细胞）是CD4+ T细胞的一个小子集，可以通过与其他各种免疫细胞相互作用来中断抗肿瘤免疫反应。本研究旨在比较骨髓瘤中Treg细胞与正常对照的表达水平。方法：采集90例健康成人的外周血和13例新诊断的骨髓瘤患者的骨髓穿刺标本。采用Duraclone IM Treg试管试剂盒进行八色流式细胞术。根据Treg细胞CD3+CD4+CD25+FoxP3+CD39+Helios+细胞的免疫表型特征，建立门控策略。结果：基于CD4+CD25+FoxP3+组合，在初始骨髓瘤诊断中证实Treg细胞比正常对照增加2.5倍。Treg细胞的增加与尿m蛋白水平呈弱正相关（r = 0.619, p < 0.05）。结论：因此，基于微环境相关的生物标志物，Treg细胞的增加可能预示着骨髓瘤更严重的并发症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical laboratory 医学-医学实验技术

CiteScore

1.50

自引率

0.00%

发文量

494

审稿时长

3 months

期刊介绍： Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.